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Abstract
Bone morphogenic protein (BMP)-7 is a member of the BMP family which are structurally and functionally related, and part
of the TGFb super family of growth factors. BMP-7 has been reported to inhibit renal fibrosis and TGFb1-induced epithelial-
mesenchymal transition (EMT), in part through negative interactions with TGFb1 induced Smad 2/3 activation. We utilized in
vivo bleomycin-induced fibrosis models in the skin and lung to determine the potential therapeutic effect of BMP-7. We
then determined the effect of BMP-7 on TGFb1-induced EMT in lung epithelial cells and collagen production by human lung
fibroblasts. We show that BMP-7 did not affect bleomycin-induced fibrosis in either the lung or skin in vivo; had no effect on
expression of pro-fibrotic genes by human lung fibroblasts, either at rest or following exposure to TGFb1; and did not
modulate TGFb1 -induced EMT in human lung epithelial cells. Taken together our data indicates that BMP-7 has no anti-
fibrotic effect in lung or skin fibrosis either in vivo or in vitro. This suggests that the therapeutic options for BMP-7 may be
confined to the renal compartment.
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Introduction
Heightened activation, altered phenotype and augmented
synthetic activity of collagen producing cells are hallmarks of
fibrosis. In the lung, fibrotic diseases such as idiopathic pulmonary
fibrosis (IPF), result in reduced lung compliance and loss of
alveolar architecture, which ultimately leads to organ failure and
death of the afflicted individual [1, 2]. Similarly, in the skin, a
significant population of people affected by diseases such as
scleroderma also have substantial fibrosis of the lungs and other
internal organs. The progressive decline in organ function in these
diseases is pronounced and unrelenting, due, in part, to the lack of
effective treatments being available.
TGFb1, is the prototypical pro-fibrotic cytokine and is over-
expressed in fibrosis in multiple human settings and animal models
[3–5]. This growth factor induces excess extracellular matrix
(ECM) generation, enhanced fibroblast survival and the differen-
tiation of fibroblasts to aSMA-positive myofibroblasts, which are
relatively absent from normal lungs [1–3]. Additionally, one of the
more recent activities ascribed to TGFb1 is epithelial to
mesenchymal transition (EMT) [4–6]. EMT is a dynamic process
by which epithelial cells undergo phenotypic transition to motile
mesenchymal cells such as fibroblasts and myofibroblasts and is
accompanied by downregulation of epithelial proteins such as E-
cadherin with a concomitant increase in mesenchymal cell
markers such as vimentin and EDA-fibronectin [7,8]. EMT has
been observed in several experimental models of fibrosis where it
has been shown to account for up to 20% of the interstitial
fibroblasts [9–12]. Several recent studies have shown that EMT
occurs in lung epithelial cells both in vitro and in vivo, supporting the
concept of EMT contributing to the fibrosis observed in IPF
[5,13,14]. However, intracellular processes that modify fibrotic
pathways and EMT in particular, have not been evaluated.
Bone morphogenic protein (BMP)-7 is a member of the BMP
family which are structurally and functionally related, and part of
the TGFb superfamily of growth factors [15]. There are three type
I and three type II receptors so far identified and any two of each
forms a heterotetramer receptor that BMP-7 can signal through
[16,17]. Binding of BMP-7 to its receptor complex results in
recruitment and phosphorylation of Smad’s 1, 5 and 8 [15,18],
which then associate with Smad 4, translocate to the nucleus and
confer gene expression [19,20]. BMP-7 has also been shown to
modulate TGFb1 signaling, by either inhibiting Smad 2/3
phosphorylation or by direct competition for Smad 4, or both
[19,20]. Accordingly, BMP-7 has also been reported to inhibit
many processes involving TGFb1 including renal fibrosis [21],
cardiac fibrosis and allograft rejection in vivo [22] as well as EMT
and at high concentrations, endothelial cell-mesenchymal transi-
tion [22]. However, in other cells, such as hepatocytes or breast
epithelial cells, BMP-7 appears to have either no effect [8] or the
PLoS ONE | www.plosone.org 1 December 2008 | Volume 3 | Issue 12 | e4039opposite effect [23], suggesting some organ specificity. In the
present study we sought to evaluate the role of BMP-7 in lung and
skin fibrosis as well its capacity to regulate the pro-fibrotic effects of
TGFb1 in vitro.
Results
BMP-7 does not inhibit intratracheal bleomycin-induced
pulmonary fibrosis
In initial experiments we correlated collagen deposition in the
lung following bleomycin administration, with the expression of
TGFb1. Mice were treated with either bleomycin or saline as a
control on day 0, with cohorts being sacrificed at days 1, 2, 4, 8,
13, 16 and 21 after intratracheal challenge. There was a significant
increase in total collagen deposition observed as early as 8 days
post-bleomycin which continued to increase until day 16, after
which levels began to decrease (Fig. 1A). Gene transcription of
TGFb1 followed a similar pattern of induction with significant
increases being noted at day 4, continuing to a maximum after 16
days and decreasing at day 21 (Fig. 1B).
Due to the reported effects of BMP-7 inhibiting TGFb1p a t h w a y ,
we systemically administered BMP-7 (500 mg/kg) to mice daily for 2
weeks. This dose level is higher than previously reported to be
efficacious[21].Thereforethe amountusedintheinvivostudies were
supramaximal than anticipated efficacious dose levels.
As peak collagen synthesis occurred between day 13 and 16,
mice were sacrificed on day 14 and lungs analyzed for collagen
production and expression of pro-fibrotic genes. As seen in
Figure 2A, we found that BMP-7 had no effect on bleomycin-
induced lung collagen deposition. Administration of rhBMP-7 also
induced the expression of IL-6 mRNA in lung tissue (Fig. 2B). To
confirm that BMP-7 did not alter the deposition of collagen or
gross pathology induced by bleomycin, we also histologically
analyzed lungs from all cohorts of animals. As expected,
bleomycin induced disorganization of normal alveolar architec-
ture, pronounced collagen accumulation and interstitial infiltrates.
Moreover, comparable histopathology was observed in the BMP-
7-treated mice (Fig. 2C). We confirmed that BMP-7 reached the
lungs we stained lung sections with an anti-BMP-7 antibody
(Fig. 2D). Moreover BMP-7 was biologically active in the lungs of
dosed mice as we observed increased phosphorylation of Smad
1,5,8 (Fig. 2D and E). Taken together, this indicated that BMP-7
had no protective or inhibitory effect on the fibrotic response
induced by intratracheal bleomycin.
Systemic BMP-7 does not inhibit subcutaneous
bleomycin-induced skin or lung collagen
Another model of fibrosis involves repeated subcutaneous
delivery of bleomycin [24], which results in an experiment model
of systemic sclerosis characterized by increased local skin collagen
deposition, as well as a subsequent increase in pulmonary collagen
deposition. This mode of bleomycin delivery results in a
substantial increase in skin and lung collagen production.
However, systemic rhBMP-7 treatment had no effect on the
deposition of collagen at either site (Fig. 3A and B). Subcutaneous
bleomycin administration also increased levels of the pro-fibrotic
chemokine JE/CCL2 in both the skin and lung, and this too was
not inhibited by rhBMP-7 treatment (Fig. 3C and D).
BMP-7 has no effect on expression of profibrotic gene in
human lung fibroblasts
Given that BMP-7 had little effect on indices of fibrosis in vivo,
we asked whether BMP-7 affected fibroblast function in vitro.
Exposure of human lung fibroblasts to TGFb1 (10 ng/ml)
upregulated expression of procollagen Ia1 (Fig. 4A), aSMA
(Fig. 4B), CTGF (Fig. 4C) and TGFb1 (Fig. 4D). Treatment with
rhBMP-7 at either 10 or 50 ng/ml had no effect on expression of
any of these genes, either alone or following treatment with
TGFb1 responses. We further evaluated aSMA at the protein level
and found that BMP-7 did not modulate baseline or TGFb-
induced aSMA expression (Fig. 4E and F). Again phosphorylation
of Smad 1,5,8 demonstrated that the exogenous rhBMP-7 was
biologically active (Fig. 4E and F).
BMP-7 does not affect TGFb-induced epithelial to
mesenchymal transition in lung epithelial cells
Given that there appears to be some degree of differences in
organ or cell specificity to BMP-7, we determined whether
rhBMP-7 could influence TGFb1-induced EMT in the human
lung epithelial cell line A549. Incubation with TGFb1 at either 10
or 50 ng/ml induced phenotypic changes consistent with EMT
(Fig. 5A). Morphologically the cells lost their rounded cobblestone
appearance and became stellate and migratory. Exposure to
TGFb1 also induced biochemical changes such as robust
expression of the mesenchymal markers EDA fibronectin (EDA-
FN) and vimentin, and a concomitant downregulation of the
epithelial markers E-Cadherin and zonula occludens-1 (ZO-1)
(Fig. 5B and C). Addition of rhBMP-7 alone had no obvious effect
Figure 1. Timecourse of bleomycin-induced lung fibrosis. (A)
Timecourse of induction of collagen protein generation in the lungs of
mice challenged with intratracheal bleomycin (filled bars) or intratra-
cheal PBS (open bars) as measured by the Sircol Assay (mean6S.E.M. of
n=4–8 mice/group). (B) Real-time RT-PCR analysis of TGFb1 (open bars)
gene expression in the lungs of mice challenged with intratracheal
bleomycin compared to PBS control (dotted line) at the same
corresponding time points (mean value of n=3 mice/group). For
differences between bleomycin challenged and corresponding time
point PBS control groups * indicates p,0.05, **p,0.01 statistical
significance difference between bleomycin and corresponding time
point PBS control.
doi:10.1371/journal.pone.0004039.g001
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PLoS ONE | www.plosone.org 2 December 2008 | Volume 3 | Issue 12 | e4039Figure 2. BMP-7 does not inhibit intratracheal bleomycin-induced pulmonary fibrosis. (A) Total soluble collagen levels in lung homogenates
frommicechallengedwithbleomycinorPBS(openbars)14dayspost-intratrachealadministration,andtreatedwithvehicle(filledbars)orBMP-7(hatched
bars) daily (mean6S.E.M.ofn=5 mice/group). (B) Real-time RT-PCR analysis ofIL-6gene expressioninthe lungs ofmicechallengedwithintratracheal PBS
(openbars)orbleomycinandtreateddailywithBMP-7 (hatchedbars) orvehicle(filledbars)for14days(mean6S.E.M ofn=3 mice/group).Representative
photomicrographs ofsectionsoflungs from mice 14 days after intratracheal delivery ofsaline (left)or 14daysafter intratracheal bleomycin and treatment
with daily injections of BMP-7 (right) or vehicle control (middle). Sections are stained with (C) haematoxylin and eosin (top panels) or PicroSirius red
(bottom panels); or immunostained for (D) BMP7 (top panels) or phosphor- Smad 1,5,8 (middle panels) expression or isotype control (bottom panels)
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time as TGFb1, rhBMP-7 (10 or 50 ng/ml) had no effect on cell
morphology or expression of EDA-FN, vimentin, ZO-1 or E-
Cadherin (Fig. 5B and C). BMP-7 signaling is mediated by BMP
receptor II and subsequent recruitment and phosphorylation of
Smad 1, 5 and 8. To confirm that BMP-7 was active, we evaluated
BMP receptor II expression and Smad 1,5,8 phosphorylation by
Western blot analysis. Comparable levels of BMPRII expression
were seen under all conditions (Fig. 5B and C). Furthermore,
BMP-7 induced a dose-dependent increase in phosphorylation of
Smad 1,5,8 in the presence or absence of TGFb1 (Fig. 5B and C)
confirming that BMP-7 signaling is activated following TGFb1
exposure. We also assessed whether BMP-7 interacted with
TGFb1 signaling, by examining phosphorylation of Smad 3 and
expression of Smad 3-dependent genes Snail-1 and Snail-2 (slug).
Exposure to rhBMP-7 had no effect on TGFb1-induced
expression of Snail-1 and -2 (Fig. 5D) or Smad 3 phosphorylation
even when used at a supramaximal concentration of 500 ng/ml
(data not shown). We extended these findings to evaluate the effect
of rhBMP-7 on primary cultures of human bronchial epithelial
cells and observed a similar phenomenon. In this setting, TGFb1
induced EMT as described above. In contrast, BMP-7 had no
Figure 3. BMP-7 does not inhibit subcutaneous bleomycin-induced skin and lung fibrosis. Total collagen in the (A) skin or (B) lungs of
mice challenged daily with subcutaneous bleomycin and treated daily with either BMP-7 (hatched bars) or vehicle control (filled bars) (mean6S.E.M.
of n=8 mice/group). JE/CCL2 protein levels were measured by luminex in (C) skin and (D) lung homogenates of subcutaneous bleomycin-challenged
mice. Each data point represents one animal, with bars representing the mean. For differences in Bleomycin challenged in comparison to naı ¨ve
control groups * indicates p,0.05, **p,0.01, ***p,0.005 statistical significance.
doi:10.1371/journal.pone.0004039.g003
Fields viewed at6200 magnification. (E) Quantification of immunostaining for the number of positive cells for BMP7 (grey bars) or phosphor- Smad 1,5,8
(black bars) in lung sections using image pro. Bars represent mean number of positive cells6S.E.M. for three sections. For differences between
bleomycin and corresponding PBS control, * indicates p,0.05, **p,0.01 statistical significance.
doi:10.1371/journal.pone.0004039.g002
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to TGFb1. This was not due to a lack of activity since we observed
increased expression of phosphorylated Smad 1,5,8 in response to
rhBMP-7 (Fig. 5E and F).
Gene silencing of BMP-7 does not modulate TGFb-
induced EMT
To further confirm that BMP-7 does not influence TGFb1-
induced EMT, we used siRNA to knock down endogenous BMP-7
gene expression. As seen in Figure 6A and C, BMP-7 siRNA
effectively decreased expression by .75%. However, despite this
level of protein suppression, A549 cells still underwent EMT as
judged by changes in morphology (data not shown) as well as
decreased expression of E-Cadherin and increased expression of
EDA-FN following exposure to TGFb1 (Fig. 5B).
Discussion
In the current study, we show that rhBMP-7: (1) did not affect
bleomycin-induced fibrosis in either the lung or skin in vivo; (2) had
no effect on expression of pro-fibrotic genes by human lung
fibroblasts, either at rest or following exposure to TGFb1; (3) did
not modulate TGFb1 -induced EMT in human lung epithelial
cells in vitro. Taken together, these data suggest BMP-7 has little
effect on fibrosis in the lung or the skin.
Previous studies have shown that bleomycin induces collagen
deposition and that TGFb1 plays an important role in mediating
this process [3,25–27]. In keeping with these findings, we found
increased TGFb1 expression that correlated with the increase in
pulmonary collagen deposition following intra-tracheal bleomycin
exposure. We also found increased BMP-7 protein expression
following intratracheal bleomycin, however we hypothesized that
the magnitude of BMP-7 induction is insufficient to modulate
TGFb1 activity in the lung. Therefore, to test this hypothesis we
treated mice with daily injections of rhBMP-7 after bleomycin
challenge. We chose a dose greater than previously demonstrated
to be efficacious in murine models of fibrosis [22]. However,
despite continual treatment for 14 days, the progression of lung
fibrosis was not modified, suggesting that in lung cells, the
inhibitory effects of BMP-7 are absent. Further, in our study there
was increased IL-6 in the lungs of rhBMP-7 treated, bleomycin-
challenged mice, indicating bioactive BMP-7. Also, immunohis-
tochemical staining of lung sections from BMP-7 treated,
bleomycin challenged animals showed increased phosphorylated
Smad 1,5,8, indicating intact BMP-7 signaling. Therefore BMP-7,
although active, was not therapeutic in our models of lung fibrosis
at the efficacious doses used in this study.
In order to further test this hypothesis, we examined whether
rhBMP-7 could ameliorate skin fibrosis induced by subcutaneous
administration of bleomycin. However, as was seen in the lung
fibrosis model, rhBMP-7 exerted no therapeutic benefit on
collagen deposition in the skin. Given that subcutaneous
bleomycin also results in lung fibrosis, akin to scleroderma-
associated lung fibrosis [28–30], we examined the lungs of the
mice involved in the dermal fibrosis study and found fibrosis that
was indistinguishable from mice not exposed to rhBMP-7.
Similarly, secretion of the pro-fibrotic chemokine JE/CCL2 in
either lung or the skin was not modified by rhBMP-7. Based on
this evidence we conclude that systemic BMP-7 treatment did not
reduce lung or skin fibrosis.
Thus, while there is ample data to suggest that BMP-7 has
potent anti-fibrotic effects on cells within the kidney [21,31], the
data from our current experiments suggests that BMP-7 has little
effect in modifying fibrosis in either the lung or the skin. Indeed,
the anti-fibrotic effects of BMP-7 in extra-renal tissues remain
controversial. For example, Valcourt and colleagues undertook an
extensive analysis of TGFb1-induced EMT in several mouse and
human epithelial cell lines [8]. The authors showed that except for
aSMA expression, BMP-7 was ineffective at reversing TGFb1
induced EMT. In our in vivo studies, we found that aSMA was the
only gene evaluated whose expression trended towards an
inhibition with rhBMP-7 treatment (data not shown) and this
supported this finding. Tacke and co-workers [23] recently
demonstrated that BMP-7 induced collagen and fibronectin
production by hepatic stellate cells and was upregulated in the
cirrhotic human liver. In contrast, Maric et al., showed that in rats
with inflammatory bowel disease, systemic administration of BMP-
7 led to less severe colitis with preserved histology and suppression
of pro-inflammatory and pro-fibrogenic genes [32]. More recently,
administration of rhBMP-7 was shown to inhibit the progression of
cardiac fibrosis in mouse models of pressure overload hypertrophy
and chronic allograft rejection [22]. The reasons underlying these
dichotomous responses are unknown at present, but clearly
warrant further investigation.
The anti-fibrotic effects of BMP-7 in renal, gastrointestinal and
cardiac fibrosis have been associated with the ability of this protein
to attenuate TGFb1-induced epithelial or endothelial cell to
mesenchymal cell transition [21,22,32]. We took advantage of
these observations since EMT has been shown in lung epithelial
cells from both mice and humans in vitro and also following
bleomycin challenge in vivo [4,13]. Exposure to TGFb1 induced
morphological characteristics of EMT, such as elongation and cell
spreading and this was associated with phosphorylation of Smad
2/3. Addition of BMP-7 at 3 different concentrations was unable
to modify these effects of TGFb1. This was not due to lack of
activity since we saw robust phosphorylation of Smad 1,5,8 in
response to BMP-7. To investigate the mechanisms behind this
lack of effect further we used two different strategies. Firstly we
examined the effect of BMP-7 on TGFb1-dependent Smad 2/3
activation and the Smad 3-dependent expression of Snail-1 and
Snail-2. We show that BMP-7 does not influence Smad-3
phosphorylation nor the induction of Snail-1 and -2 alone or
following TGFb1 exposure. We confirmed this finding in primary
cultures of normal human bronchial epithelial cells. In these cells,
addition of rhBMP-7 had no effect on epithelial cell morphology
or indices of cell signaling and did not modulate TGFb1-induced
EMT, despite inducing robust phosphorylation of Smad 1,5,8. In
the final set of experiments, we used targeted siRNA to selectively
knockdown BMP-7 expression. This strategy also had no effect on
TGFb1-driven EMT. These three independent streams of data
provide further evidence for a lack of effect of BMP-7 in pro-
fibrotic processes in lung epithelial cells. This hypothesis of tissue
specificity is reinforced by the fact that we used a similar
concentration range of BMP-7 (10 and 50 ng/ml) to that used
Figure 4. BMP-7 does not inhibit TGFb1 induced gene expression in fibroblasts. Primary human lung fibroblasts (n=3) were serum starved
for 24 hours before incubation with rhBMP-7 at 10 or 50 ng/ml for one hour and then stimulated with rhTGFb1 for 24 hours. Relative changes in
mRNA expression of (A) procollagen-1, (B) aSMA, (C) CTGF and (D) TGFb1 were analyzed using real-time RT-PCR. Protein expression of aSMA and
phosphoSMAD 1,5,8, was (E) visualized and (F) quantitated to b-tubulin by Western blot analysis. * indicates p,0.05 significant difference in
comparison to unstimulated cells.
doi:10.1371/journal.pone.0004039.g004
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PLoS ONE | www.plosone.org 6 December 2008 | Volume 3 | Issue 12 | e4039Figure 5. BMP-7 does not inhibit TGFb1 induced EMT in A549 cells. A549 cells (n=5) were serum starved for 24 hours before treatment with
rhBMP-7 (10 or 50 ng/ml) for 24 hours followed by the presence or absence of rhTGFb1 (10 ng/ml). (A) Phenotypic changes by light microscopy were
noted in A549 cells cultured in medium with 0.5% serum and TGFb1 (10 ng/ml) which were not attenuated by pre-incubation with BMP-7 at 10 or
50 ng/ml. (B) Snail-1 and Snail-2 gene expression was determined using real time RT-PCR in RNA isolated A549 cells after 48 hours of stimulation with
BMP-7 (10 or 50 ng/ml) or TGFb1 (10 ng/ml) alone or in combination, experiments were run in triplicate. (C) Western blot analysis of A549 lysates for
the mesenchymal markers Fibronectin-EDA and vimentin, an epithelial markers E-Cadherin and ZO-1, BMP receptor II and phospho- Smad 1, 5, 8
expression following stimulation with BMP-7 alone or in combination with TGFb1 for 48 or 72 hours. b-actin was used as a protein loading control. (D)
Densitometric analysis of EDA-Fn a, E-Cadherin & and phospho- Smad 1,5,8, % expression shown in Figure 5C. (E) Western blot analysis of normal
human bronchial epithelial lysates for Fibronectin-EDA, E-cadherin, phospho Smad 3, phospho Smad 1,5,8 expression following stimulation with
BMP-7 alone or in combination with TGFb1 for 72 hours. b-actin was used as a protein loading control. (F) Densitometric analysis of EDA-Fn a,E -
Cadherin & and phospho- Smad 1, 5, 8 %expression shown in Figure 5E.
doi:10.1371/journal.pone.0004039.g005
No Antifibrotic Effect of BMP7
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proximal tubular epithelial cells (10 and 100 ng/ml). Further
evidence is provided by Kalluri and colleagues [22] in which
effective doses of 1000 ng/ml of BMP-7 were required to inhibit
endothelial-mesenchymal transition in the heart. However in our
studies, supramaximal concentration of BMP-7 (500 ng/ml) also
had no modulatory effect on TGFb1-induced EMT.
Another cell intimately linked with the development of fibrosis is
the fibroblast. In these cells, TGFb1 mediates a variety of pro-
fibrotic features including enhancing collagen production and
growth factor synthesis [34,35]. Consistent with the epithelial cell
data, BMP-7 had no effect on these cells, either alone or following
TGFb1- mediated changes in gene expression.
Taken together we have shown that BMP-7 has no anti-fibrotic
effect in lung fibrosis either at the in vivo or in vitro level. This
suggests that the therapeutic options for BMP-7 may be confined
to the renal compartment. This is supported by the fact that BMP-
7 null mice die perinatally from renal failure [36].
Materials and Methods
Animal models of fibrosis
All experiments were conducted under Centocor IACUC
regulations and protocols. Female C57Bl/6 mice (6–8 wk old)
were purchased from ACE Laboratories (Boyertown, PA, USA).
Mice were maintained in specific pathogen-free conditions and
provided with food and water ad libitum. To induce intratracheal
bleomycin-induced pulmonary fibrosis, mice were treated with
intratracheal bleomycin (Blenoxane, Sigma, St. Louis, MO) on
day 0, as previously described [37,38]. Briefly, mice were
anesthetized by intraperitoneal injection of 250 ml of 12.5 mg/
ml ketamine followed by intratracheal instillation of 0.04 U of
bleomycin in 50 ml of sterile PBS. Mice were analyzed for up to 21
days after bleomycin administration. Control animals received
intratracheal sterile saline. For the studies evaluating the effect of
BMP-7 on bleomycin-induced lung fibrosis, animals challenged
with bleomycin were separated into two groups where they
received vehicle control (20 mM acetate, pH 4.5 and 5%
mannitol) or BMP-7 (500 mg/kg, i.p). For the subcutaneous
bleomycin-induced skin and lung fibrosis model, mice backs were
shaved and bleomycin administered subcutaneously daily for over
2 weeks. Control mice were injected daily with BMP-7 (500 mg/
kg, i.p) or vehicle control (20 mM acetate, pH 4.5 and 5%
mannitol) or PBS in the same anatomical site as the bleomycin
mice. BMP-7 is well conserved between mouse and man (98% at
the amino acid level [39]). Further, the recombinant human form
has been used in several previous studies using murine models.
Therefore in the present study, as in prior in vivo studies, we
utilized human BMP-7 in our mouse models.
Histology
Lungs were perfused in situ through the right ventricle with
saline and then inflated under a constant pressure of 30 cm H2O
with 1a ml of 10% normal buffered formalin (NBF). Lungs were
ligated at the trachea, removed en bloc, and immersed in NBF for
24 hr. After which, tissue samples were changed to 70% alcohol
before paraffin embedding, followed by sectioning, hematoxylin
and eosin or Sirius Red staining. Sections were examined using a
Fisher Scientific Micromaster inverted microscope and camera
(Pittsburgh, PA, USA). For immunohistochemical analysis, five
slides from each group containing 3 mice were stained separately
to identify BMP-7 and phospho- Smad 1, 5, 8. Sections were de-
paraffinized and rehydrated, and subject to antigen retrieval
Figure 6. BMP-7 knock-down does not augment the ability of TGFb1 to induced EMT in A549 cells. (A) Representative photomicrographs
of A549 cultures (n=3) transfected with BMP-7 siRNA (10 or 50 ng/ml), or non-silencing scrambled siRNA for 24 hours followed by the presence or
absence of rhTGFb1 (10 ng/ml) for 72 hours. (B) Western blot analysis of A549 cell lysates indicated increased expression of mesenchymal marker
Fibronectin-EDA and loss of epithelial marker E-Cadherin following rhTGFb1 treatment which was not enhanced following endogenous knock down
of BMP-7. (C) Western blot analysis of BMP-7 showed efficient knock down of the protein following BMP-7 siRNA treatment.
doi:10.1371/journal.pone.0004039.g006
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H2O2 and blocked for 20 min with 50% goat serum. Primary
mouse anti human BMP-7 (rabbit polyclonal, abcam, Cambridge,
MA) and phospho- Smad 1,5,8 (rabbit polyclonal, Cell Signa-
lingTechnology, Denvers, MA) or isotype control (normal rabbit
IgG, Santa Cruz Biotechnologies, Santa Cruz, CA) were added
overnight at 4uC in 25% goat serum. Sections were then incubated
with a biotinylated goat anti-rabbit secondary antibody (Vector
Labs Burlingame, CA) for 60 min followed by a 10 min treatment
with Streptavidin-HRP (Dako, Mississauga, ON). The antigen of
interest was visualized by using the brown chromogen 3,3-
diaminobenzidine (Dako, Mississauga, ON) and counterstained
with Harris Hematoxylin Solution (Sigma, Oakville, ON). Sections
were then dehydrated and mounted with Cytoseal 60 (Richard-
Allan Scientific, Kalamazoo, MI). Antibody dilutions and all
washes were in TRIS-buffered saline solution.
For analysis all images were viewed and captured at 2006
magnification. Five randomly selected digital 4256425 micron
fields per slide were obtained with the use of a light microscope
(Nikon Microphoto) equipped with a digital camera (JVC3-CCD
KY F-70, Diagnostic Instruments). The same field was used to
identify total cells and cells expressing BMP-7 and phosphor-
Smad 1,5,8. Image analysis was performed using Image-Pro Plus
(Media Cybernetics, Silver Spring, Maryland).
Tissue preparation for protein and RNA analyses
For protein analysis, lungs from all groups of mice were
homogenized in complete protease inhibitor (Roche Diagnostics
Corp, Indianapolis, Indiana, USA) as previously described [37].
Homogenates were centrifuged at 9006g for 10 minutes and
frozen at 280uC until time of analysis. For RNA analysis, lungs
were removed, homogenized in PBS and RNA was isolated using
RNeasy Plus Mini-Kits (QIAGEN, Valencia, CA). Purified RNA
was treated with DNAse and reverse transcribed into cDNA using
TaqManH Reverse Transcription Reagents (Applied Biosystems,
Foster City, CA). Gene expression was determined by real-time
PCR using the TaqmanH Universal PCR Master Mix (Applied
Biosystems) and pre-developed TaqmanH Gene Expression Assays
designed by Applied Biosystems, as per manufacturer’s instructions.
Fold induction was determined after calibration of the gene of
interest with 18S rRNA and normalization to either saline control
gene expression or for the effect of BMP-7 treatment, after
normalization to vehicle control bleomycin-challenged mice.
For skin fibrosis studies, on the day after the final bleomycin
injection, the skin at the injection site was removed by using an
8 mm dermal biopsy punch (Miltex, York PA) and processed for
protein or RNA as described above.
Sircol Collagen assay
The Sircol collagen assay (Biocolor Ltd., Belfast, Ireland) was
performed following the manufacturer’s instructions [40]. Briefly,
Sirius red reagent was added to each lung homogenate (50 ml) and
mixed for 30 minutes at room temperature. The collagen–dye
complex was precipitated by centrifugation at 16,000 g for
5 minutes and the pellet was resuspended in 1 ml of 0.5 M
NaOH. The concentration of collagen in each sample was
measured as absorbance at 540 nm and values extrapolated from
a known standard curve as per manufacturer’s instructions.
Chemokine levels were measured using luminex technology
(Biosource, Invitrogen, Carlsbad, CA).
Fibroblast and epithelial protein and gene expression
Pulmonary fibroblasts were isolated from lung tissue obtained
from human transplant donor lungs deemed unsuitable for
transplantation (n=4) and donated for medical research obtained
through the International Institute for the Advancement of
Medicine (Edison, NJ). The ethic committees of the involved
institutions approved this study. All fibroblast cell lines were
isolated by serial passaging and purity assessed using morpholog-
ical and immunohistochemical staining as previously described
[41]. Fibroblasts were plated into 6 well plates (Costar, Corning,
NY) at 1610
5 cells/well and allowed to adhere for 8 hours. The
cells were then washed with PBS and cultured overnight in serum
free DMEM media containing 1% penicillin and 1% streptomycin
at 37uCi n5 %C 0 2/air. Cells were then stimulated with or without
recombinant human BMP-7 (rhBMP-7; RnDSystems, Minneapo-
lis, USA) or TGFb1 (Santa Cruz Biotechnology, USA), or both
combined at 10 and 50 nM concentrations for 24 hrs. Superna-
tants were removed and RNA was subsequently isolated and
analyzed by real-time PCR as described above. Here, fold
induction was determined after calibration of the gene of interest
with 18S rRNA and normalized to corresponding unstimulated
cells. Epithelial Snail 1 and Snail 2 gene expression was evaluated
in A549 cells stimulated with BMP-7 or TGFb1 alone or in
combination. Protein levels of aSMA and phospho- Smad 1,5,8
were analyzed by Western analysis and normalized to b-tubulin
which served as the loading control.
EMT Analysis
Experiments were performed in the A549 cell line and normal
bronchial epithelial cells (NHBE; Lonza Canada Inc, Shawinigan)
both grown to 60% confluence in 6 well plates (Costar, Corning,
NY). A549 cells were grown in DMEM containing 10% fetal
bovine serum and NHBE cells grown in bronchial epithelial
growth media (BEGM, Cambrex, Lonza Canada Inc). All cultures
were maintained at 37uC, 5% CO2/air. Prior to each experiment,
cells were incubated in respective serum free media for 24 hrs.
A549 and NHBE cells were then incubated with or without
rhBMP-7 or TGFb1 or both combined at 10 and 50 nM
concentrations for 48 and 72 hrs. Following this, cells were lysed
in complete protease inhibitor (Roche Diagnostics Corp). Lysates
at a concentration of 50 ng/ml were then electrophoresed in
SDS-polyacrylamide gels, electrotransferred to nitrocellulose,
and membranes underwent Western analysis with antibodies
directed against fibronectin-EDA (MAB1940,Chemicon Interna-
tional, Temecula, USA), E-Cadherin (Clone G 10, Santa Cruz
Biotechnology, USA); phospho- Smad 1,5, & 8, (AB3848)
BMP receptor II (MAB3551), and rhBMP-7 (RnD Systems). b-
tubulin (Upstate, Lake Placid, NY) was used and protein loading
control.
BMP-7 knock-down with SiRNA
A549 cells grown to 50% confluence in six well plates were
transfected with ON-TARGET plus SMART pool BMP-7 SiRNA
(Dharmacon, Chicago, USA) or non-silencing control siRNA at a
final concentration of 10 or 50 nM using Hyperfect (Quiagen,
USA) in DMEM containing 10% fetal bovine serum at 37uC, 5%
C02. After 24 hrs, cells were incubated in DMEM containing
0.5% serum for a further 24 hrs, and then incubated with
TGFb1at 10 nM for 48 hrs. Cells were then lysed and analyzed by
Western blot as above.
Statistical analysis
All statistical analysis were calculated using GraphPad Prism
software (San Diego, CA). All statistical comparisons were
performed using nonparametric Mann Whitney t-test. Data was
considered significant if p,0.05, p,0.01 or p,0.005, which is
referred to as *, ** or *** respectively.
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